Building upon the success achieved by immunotherapy targeting immune checkpoints in various cancers27,28, including promising results from clinical trials, our findings suggest that modulating the tumor microenvironment and targeting GBM through inhibition of RAB32 could be a potential therapeutic strategy. Here, RAB32 is linked to neoplasm.